Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society Annual Meeting
PRRUF Stock | USD 0.20 0.00 0.00% |
Roughly 62% of Immutep's investor base is looking to short. The analysis of overall sentiment of trading Immutep Limited pink sheet suggests that many investors are alarmed at this time. The current market sentiment, together with Immutep's historical and current headlines, can help investors time the market. In addition, many technical investors use Immutep Limited stock news signals to limit their universe of possible portfolio assets.
Immutep pink sheet news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Immutep daily returns and investor perception about the current price of Immutep Limited as well as its diversification or hedging effects on your existing portfolios.
Immutep |
Novel Nonpeptide Drug Conjugate Platform to be Debuted, Featuring Preclinical Profile of Lead Candidate CRN09682 Targeting SST2-Expressing Tumors, which is...
Read at globenewswire.com
Immutep Fundamental Analysis
We analyze Immutep's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immutep using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Immutep based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Working Capital
Working Capital Comparative Analysis
Immutep is currently under evaluation in working capital category among its peers. Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
Immutep Limited Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Immutep pink sheet to make a market-neutral strategy. Peer analysis of Immutep could also be used in its relative valuation, which is a method of valuing Immutep by comparing valuation metrics with similar companies.
Peers
Immutep Related Equities
IMMX | Immix Biopharma | 5.48 | ||||
CRNX | Crinetics Pharmaceuticals | 5.21 | ||||
DSGN | Design Therapeutics | 4.23 | ||||
APLT | Applied Therapeutics | 2.48 | ||||
AADI | Aadi Bioscience | 1.67 | ||||
CYTK | Cytokinetics | 0.30 | ||||
CGEM | Cullinan Oncology | 0.24 | ||||
ALVR | Allovir | 0.73 | ||||
GPCR | Structure Therapeutics | 1.30 | ||||
CDTX | Cidara Therapeutics | 1.58 | ||||
VRDN | Viridian Therapeutics | 1.96 | ||||
ENVB | Enveric Biosciences | 2.47 | ||||
ZNTL | Zentalis Pharmaceuticals | 3.05 | ||||
CTMX | CytomX Therapeutics | 3.31 | ||||
ALXO | Alx Oncology | 3.80 | ||||
ELEV | Elevation Oncology | 4.00 | ||||
SANA | Sana Biotechnology | 5.65 | ||||
ZURA | Zura Bio | 9.71 | ||||
OLMA | Olema Pharmaceuticals | 12.76 | ||||
SLN | Silence Therapeutics | 12.84 | ||||
ADCT | ADC Therapeutics | 36.21 |
Complementary Tools for Immutep Pink Sheet analysis
When running Immutep's price analysis, check to measure Immutep's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immutep is operating at the current time. Most of Immutep's value examination focuses on studying past and present price action to predict the probability of Immutep's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immutep's price. Additionally, you may evaluate how the addition of Immutep to your portfolios can decrease your overall portfolio volatility.
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |